Twist Bioscience Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed on November 21, 2018, reporting events occurring on November 15, 2018, and November 19, 2018. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements approved by the Compensation Committee of the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
Material Changes
The Compensation Committee approved significant salary increases and new annual bonus targets for Named Executive Officers (NEOs) effective for the fiscal year 2019:
- Emily M. Leproust (CEO): Base salary increased from $362,250 to $500,000 (38.03% increase). New annual bonus target set at 80%.
- James M. Thorburn (CFO): Base salary increased from $305,000 to $400,000 (31.15% increase). New annual bonus target set at 50%. Note: Mr. Thorburn commenced employment in April 2018 and earned $134,015 in 2018.
- Mark Daniels (SVP, CLO, CEO, Secretary): Base salary increased from $325,000 to $360,000 (10.77% increase). New annual bonus target set at 50%. His title was updated effective November 19, 2018.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on business performance, risks, contingencies, or unusual items. The document is strictly limited to the disclosure of executive compensation changes.
Investor Verification Checklist
- Verify the effective dates of the salary increases (November 15, 2018, for the CEO; December 1, 2018, for the CFO and SVP).
- Confirm the new annual bonus target percentages (80% for CEO, 50% for CFO and SVP) for the fiscal 2019 performance period.
- Review the updated job title for Mark Daniels effective November 19, 2018.
- Note that the 2018 base salary for the CFO represents a full-year figure, not actual earnings for the partial year of employment.